March 29 (Reuters) - Eli Lilly LLY.N will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine 3696.HK, which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Reuters could not immediately verify the report.